Morepen Laboratories (NSE:MOREPENLAB) Total Liabilities : ₹4,460 Mil (As of Mar. 2024)

View and export this data going back to 1999. Start your Free Trial

What is Morepen Laboratories Total Liabilities?

Morepen Laboratories's Total Liabilities for the quarter that ended in Mar. 2024 was ₹4,460 Mil.

Morepen Laboratories's quarterly Total Liabilities declined from Sep. 2023 (₹4,052.48 Mil) to Dec. 2023 (₹0.00 Mil) but then increased from Dec. 2023 (₹0.00 Mil) to Mar. 2024 (₹4,459.79 Mil).

Morepen Laboratories's annual Total Liabilities declined from Mar. 2022 (₹4,919.52 Mil) to Mar. 2023 (₹3,580.47 Mil) but then increased from Mar. 2023 (₹3,580.47 Mil) to Mar. 2024 (₹4,459.79 Mil).

Morepen Laboratories Total Liabilities Historical Data

The historical data trend for Morepen Laboratories's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Morepen Laboratories Total Liabilities Chart

Morepen Laboratories Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Total Liabilities

Get a 7-Day Free Trial

3,798.66

4,338.56

4,919.52

3,580.47

4,459.79

Morepen Laboratories Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial															3,580.47	-	4,052.48	-	4,459.79

Morepen Laboratories Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Morepen Laboratories's Total Liabilities for the fiscal year that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	4020.446	+	(33.64	+	405.703
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	4,460

Total Liabilities	=	Total Assets (A: Mar. 2024 )	-	Total Equity (A: Mar. 2024 )
	=	12932.051	-	8472.262
	=	4,460

Morepen Laboratories's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	4020.446	+	(33.64	+	405.703
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	4,460

Total Liabilities	=	Total Assets (Q: Mar. 2024 )	-	Total Equity (Q: Mar. 2024 )
	=	12932.051	-	8472.262
	=	4,460

Morepen Laboratories Total Liabilities Related Terms

Thank you for viewing the detailed overview of Morepen Laboratories's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Morepen Laboratories (NSE:MOREPENLAB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Morepen Laboratories Ltd (NSE:MOREPENLAB) » Definitions » Total Liabilities

Traded in Other Exchanges

500288:India

Address

2nd Floor, Tower C, DLF Cyber Park, Udyog Vihar-III, Sector 20, Gurugram, HR, IND, 122016

Website

https://www.morepen.com

Morepen Laboratories Ltd is an India based pharmaceutical company. It develops, manufactures and markets generic drugs and pharmaceutical formulations. The company's products includes Tablets, Capsules, Injections, Ointments, Syrups, and Powders. It also offers products under brands Burnol, Lemolate and Fiber-X. The company's geographical markets include India, the United States and the rest of the world, with a majority of revenue being generated in India.

Morepen Laboratories (NSE:MOREPENLAB) Headlines

No Headlines